Biosimilars are currently being used in clinical practice for the supportive care of patients with cancer, such as hematopoietic growth factors (e.g., erythropoietin, filgrastim).1 In the next few years, a number of biologics used for the treatment of patients with cancer will lose exclusivity, including the monoclonal antibodies (mAbs) trastuzumab, rituximab, cetuximab, and bevacizumab. This evidence concerns the gene EPO and cancer.